Raymond James Financial Inc. Invests $3.96 Million in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Raymond James Financial Inc. bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 199,953 shares of the company's stock, valued at approximately $3,955,000. Raymond James Financial Inc. owned 0.28% of Kiniksa Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in KNSA. KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals during the 4th quarter worth $158,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after buying an additional 1,004 shares during the period. Teacher Retirement System of Texas lifted its stake in Kiniksa Pharmaceuticals by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after acquiring an additional 719 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Kiniksa Pharmaceuticals in the fourth quarter worth approximately $258,000. Finally, New York State Common Retirement Fund grew its holdings in Kiniksa Pharmaceuticals by 12.4% during the 4th quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock worth $302,000 after acquiring an additional 1,680 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

KNSA has been the subject of several recent analyst reports. Wedbush reaffirmed an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Citigroup began coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $38.00.

Insider Activity at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company's stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ross Moat sold 18,259 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the sale, the insider now owns 9,415 shares of the company's stock, valued at approximately $191,030.35. The trade was a 65.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 218,548 shares of company stock worth $5,210,745 in the last 90 days. 54.57% of the stock is owned by insiders.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA traded down $0.05 during midday trading on Friday, reaching $27.69. 179,328 shares of the stock were exchanged, compared to its average volume of 476,249. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $28.15. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -198.06 and a beta of 0.31. The business's 50-day moving average price is $21.61 and its 200 day moving average price is $21.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm's revenue for the quarter was up 72.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.25) earnings per share. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.